Information Provided By: 
Fly News Breaks for July 29, 2015
GWPH
Jul 29, 2015 | 06:57 EDT
Piper Jaffray analyst Joshua Schimmer says GW Pharmaceuticals remains a top mid-cap pick for the remainder of the year. The Phase 3 data for Epidiolex in Dravet Syndrome and Lennox Gastaut will shape future prospects for the company, Schimmer tells investors in a research note. He is "confident in prospects for success" and keeps an Overweight rating on GW with a $147 price target.
News For GWPH From the Last 2 Days
There are no results for your query GWPH
